SAIPARENT · Healthcare · Drug Manufacturers - General
Composite scorecard: 40/100 — Quality 40
| Share price | ₹567.90 |
| Market cap | ₹2,598 Cr |
| P/E ratio | 131.6 |
| P/B ratio | 3.9 |
| ROE | 147.5% |
| ROCE | 17.9% |
| Book value | ₹149.95 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹381 Cr | ₹14 Cr | 10.0% |
| 2025 | ₹163 Cr | ₹14 Cr | 24.0% |
| 2024 | ₹154 Cr | ₹8 Cr | 21.0% |
| 2023 | ₹97 Cr | ₹4 Cr | 19.0% |
Sai Parenteral's Limited, a pharmaceutical formulations company, engages in the branded generic formulations and contract development and manufacturing businesses in India and internationally. Its portfolio includes formulation products across various therapeutic areas, such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, and dermatology in various dosage forms, including injectables, tablets, capsules, liquid orals, and ointments. The company was founded in 1988 and is based in Hyderabad, Ind